Broken Heart Syndrome (Takotsubo Syndrome, Stress Cardiomyopathy)

 Broken Heart Syndrome (Takotsubo Syndrome, Stress Cardiomyopathy)

Definition

Broken heart syndrome, also known as Takotsubo syndrome (TTS), is an acute, reversible heart failure syndrome characterized by transient left ventricular systolic dysfunction, usually triggered by intense emotional or physical stress, in the absence of obstructive coronary artery disease sufficient to explain the presentation.

Epidemiology

Predominantly affects postmenopausal women (≈85–90%)

Accounts for 1–3% of patients presenting with suspected acute coronary syndrome (ACS)

Increasing recognition due to routine coronary angiography and cardiac MRI

Pathophysiology (Guideline-based concepts)

Exact mechanism remains multifactorial and incompletely understood. Current ESC and international consensus emphasize:

Catecholamine excess

Sudden surge in catecholamines leading to myocardial stunning, microvascular dysfunction, and direct myocyte toxicity

Coronary microvascular dysfunction

Impaired coronary flow reserve without epicardial obstruction

Myocardial energy metabolism impairment

Switch to inefficient energy utilization causing transient systolic dysfunction

Estrogen deficiency

Explains female predominance and increased vulnerability to catecholamine-mediated injury

Triggers

Emotional stress

Bereavement, fear, anger, bad news

Physical stress

Sepsis, stroke, surgery, trauma, acute respiratory failure

Neurologic and psychiatric conditions

Subarachnoid hemorrhage, epilepsy, anxiety, depression

Clinical Presentation

Typically mimics ACS

Acute chest pain

Dyspnea

Syncope or cardiogenic shock (severe cases)

Arrhythmias and acute heart failure may occur

Electrocardiogram Findings

Dynamic and evolving changes:

ST-segment elevation (often modest, diffuse)

ST depression (less common)

Deep T-wave inversions (subacute phase)

QTc prolongation (important predictor of ventricular arrhythmias)

Cardiac Biomarkers

Troponin: mildly to moderately elevated (disproportionately low relative to LV dysfunction)

BNP / NT-proBNP: markedly elevated (often higher than ACS)

Imaging Features

Echocardiography

Transient regional wall motion abnormalities extending beyond a single coronary territory

Typical patterns: Apical ballooning (classic, ~75–80%)

Mid-ventricular

Basal (reverse Takotsubo)

Focal

Coronary Angiography

Mandatory in suspected ACS presentation

No culprit obstructive coronary disease or plaque rupture explaining LV dysfunction

Cardiac MRI (Guideline recommended when diagnosis uncertain)

Key findings: Myocardial edema on T2-weighted imaging

Absence of late gadolinium enhancement (distinguishes from MI and myocarditis)

Diagnostic Criteria (International / ESC-endorsed principles)

1. Transient LV systolic dysfunction (regional wall motion abnormalities beyond a single epicardial coronary territory)

2. Triggering emotional, physical, or combined stress (not mandatory)

3. New ECG abnormalities or modest troponin elevation

4. Absence of infectious myocarditis (preferably excluded by CMR)

5. No culprit coronary artery disease explaining the dysfunction

6. Recovery of ventricular function on follow-up imaging

Important: Presence of coronary artery disease does not exclude Takotsubo syndrome if it does not explain the LV dysfunction.

Differential Diagnosis

Acute coronary syndrome

Myocarditis

MINOCA

Pheochromocytoma-related cardiomyopathy

Acute decompensated heart failure

Management (Guideline-Directed, Evidence-Based)

Acute Phase

Treat initially as ACS until diagnosis confirmed

Hemodynamically stable patients

Beta-blockers (to blunt catecholamine effect)

ACE inhibitors or ARBs (improve LV recovery and outcomes)

Diuretics if congested

Avoid inotropes if possible

Hemodynamic instability or shock

Exclude LV outflow tract obstruction (LVOTO) first

If LVOTO present: Avoid inotropes

Use beta-blockers

Volume expansion

Phenylephrine may be considered

If no LVOTO: Careful use of inotropes or mechanical circulatory support (IABP, Impella, VA-ECMO) if needed

Anticoagulation

Indicated if: Severe LV dysfunction

Apical akinesia with LV thrombus or high thrombus risk

Continue until LV recovery documented

Arrhythmia Management

Monitor QTc closely

Avoid QT-prolonging drugs

Treat ventricular arrhythmias per standard protocols

Long-Term Management and Follow-Up

ACE inhibitors / ARBs

Recommended for at least 3–6 months or until full LV recovery

Associated with improved survival in observational studies

Beta-blockers

May reduce recurrence, though evidence is inconsistent

Often continued long-term, especially in stress-triggered cases

Repeat Echocardiography

At 4–6 weeks to document recovery

Complete normalization of LV function is typical

Prognosis

Previously considered benign, now recognized as a serious condition

In-hospital mortality: 3–5%

Comparable long-term mortality to ACS

Recurrence rate: 5–10%

Triggers and male sex associated with worse outcomes

Complications

Acute heart failure

Cardiogenic shock

Ventricular arrhythmias

LV thrombus and embolic stroke

Mitral regurgitation

LV outflow tract obstruction

Key Guideline Take-Home Messages

Takotsubo syndrome is an acute heart failure syndrome, not benign

Always rule out ACS with coronary angiography in acute presentations

Cardiac MRI is central to diagnosis and exclusion of myocarditis

ACE inhibitors or ARBs are the cornerstone of therapy during recovery

Prognosis depends on trigger type, comorbidities, and complications

Structured follow-up is mandatory despite apparent recovery

For more cardiology-focused, guideline-based educational content, visit drmusmanjaved.com